Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Continues Diversification By Hiring French COO From GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK vaccines executive Christophe Weber will join Takeda as chief operating officer next spring and could be installed as the Japanese pharma’s next CEO a year later. Ironically, Weber negotiated a joint venture with Takeda competitor Daiichi Sankyo in 2012 to challenge Takeda’s primacy in the Japanese vaccines market.

You may also be interested in...



Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada

In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.

Market Brief: Stroke Devices Projected Sustained Growth Through To 2025

A new report from Informa's Meddevicetracker outlines the market drivers and competitive landscape for the carotid artery stents and embolic protection devices market.

Convenience Kits Recalled Because They Include High-Risk Monoject Syringes From Cardinal Health

More than 9,000 of the kits made by Aligned Medical Solutions have been recalled because they include a prefilled saline syringe that was the subject of a high-risk class I recall.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel